Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more
Hainan Honz Pharmaceutical Co (300086) - Net Assets
Latest net assets as of September 2025: CN¥1.07 Billion CNY
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has net assets worth CN¥1.07 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.88 Billion) and total liabilities (CN¥805.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.07 Billion |
| % of Total Assets | 57.14% |
| Annual Growth Rate | 14.54% |
| 5-Year Change | -27.25% |
| 10-Year Change | -36.72% |
| Growth Volatility | 155.61 |
Hainan Honz Pharmaceutical Co - Net Assets Trend (2007–2024)
This chart illustrates how Hainan Honz Pharmaceutical Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hainan Honz Pharmaceutical Co (2007–2024)
The table below shows the annual net assets of Hainan Honz Pharmaceutical Co from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | -15.44% |
| 2023-12-31 | CN¥1.38 Billion | +1.66% |
| 2022-12-31 | CN¥1.36 Billion | -12.75% |
| 2021-12-31 | CN¥1.55 Billion | -3.00% |
| 2020-12-31 | CN¥1.60 Billion | 0.00% |
| 2019-12-31 | CN¥1.60 Billion | -3.13% |
| 2018-12-31 | CN¥1.65 Billion | -13.91% |
| 2017-12-31 | CN¥1.92 Billion | +2.57% |
| 2016-12-31 | CN¥1.87 Billion | +1.68% |
| 2015-12-31 | CN¥1.84 Billion | +2.05% |
| 2014-12-31 | CN¥1.80 Billion | -0.30% |
| 2013-12-31 | CN¥1.81 Billion | -3.39% |
| 2012-12-31 | CN¥1.87 Billion | +1.06% |
| 2011-12-31 | CN¥1.85 Billion | +1.39% |
| 2010-12-31 | CN¥1.83 Billion | +660.36% |
| 2009-12-31 | CN¥240.49 Million | +59.89% |
| 2008-12-31 | CN¥150.41 Million | +29.79% |
| 2007-12-31 | CN¥115.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hainan Honz Pharmaceutical Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 93513.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥455.12 Million | 39.93% |
| Other Components | CN¥949.67 Million | 83.31% |
| Total Equity | CN¥1.14 Billion | 100.00% |
Hainan Honz Pharmaceutical Co Competitors by Market Cap
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SEC Electric Mach Co Ltd
SHG:603988
|
$371.11 Million |
|
MITSUBISHI KAKOKI
F:893
|
$371.13 Million |
|
Beihai Gofar Marine Biological Industry Co Ltd
SHG:600538
|
$371.16 Million |
|
Hapvida Participações e Investimentos S.A.
SA:HAPV3
|
$371.32 Million |
|
Le Travenues Technology Ltd
NSE:IXIGO
|
$371.04 Million |
|
Movado Group Inc
NYSE:MOV
|
$370.98 Million |
|
Veradigm Inc.
NASDAQ:MDRX
|
$370.81 Million |
|
GSR III Acquisition Corp. Unit
NASDAQ:GSRTU
|
$370.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hainan Honz Pharmaceutical Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,344,759,445 to 1,139,922,413, a change of -204,837,032 (-15.2%).
- Net loss of 216,208,517 reduced equity.
- Dividend payments of 19,872,395 reduced retained earnings.
- Other factors increased equity by 31,243,880.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-216.21 Million | -18.97% |
| Dividends Paid | CN¥19.87 Million | -1.74% |
| Other Changes | CN¥31.24 Million | +2.74% |
| Total Change | CN¥- | -15.23% |
Book Value vs Market Value Analysis
This analysis compares Hainan Honz Pharmaceutical Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 22.73x to 3.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.38 | CN¥8.73 | x |
| 2008-12-31 | CN¥0.45 | CN¥8.73 | x |
| 2009-12-31 | CN¥0.71 | CN¥8.73 | x |
| 2010-12-31 | CN¥4.54 | CN¥8.73 | x |
| 2011-12-31 | CN¥3.94 | CN¥8.73 | x |
| 2012-12-31 | CN¥3.98 | CN¥8.73 | x |
| 2013-12-31 | CN¥3.84 | CN¥8.73 | x |
| 2014-12-31 | CN¥3.83 | CN¥8.73 | x |
| 2015-12-31 | CN¥3.91 | CN¥8.73 | x |
| 2016-12-31 | CN¥4.00 | CN¥8.73 | x |
| 2017-12-31 | CN¥4.11 | CN¥8.73 | x |
| 2018-12-31 | CN¥3.43 | CN¥8.73 | x |
| 2019-12-31 | CN¥3.33 | CN¥8.73 | x |
| 2020-12-31 | CN¥3.34 | CN¥8.73 | x |
| 2021-12-31 | CN¥3.34 | CN¥8.73 | x |
| 2022-12-31 | CN¥2.92 | CN¥8.73 | x |
| 2023-12-31 | CN¥2.99 | CN¥8.73 | x |
| 2024-12-31 | CN¥2.50 | CN¥8.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hainan Honz Pharmaceutical Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -45.73%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.73x
- Recent ROE (-18.97%) is below the historical average (5.20%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 29.51% | 35.64% | 0.68x | 1.22x | CN¥22.61 Million |
| 2008 | 32.93% | 36.46% | 0.66x | 1.37x | CN¥34.48 Million |
| 2009 | 40.57% | 44.60% | 0.74x | 1.22x | CN¥73.53 Million |
| 2010 | 7.62% | 44.30% | 0.17x | 1.04x | CN¥-43.54 Million |
| 2011 | -0.06% | -0.37% | 0.15x | 1.11x | CN¥-177.88 Million |
| 2012 | 1.26% | 6.12% | 0.19x | 1.10x | CN¥-156.42 Million |
| 2013 | 0.86% | 4.80% | 0.16x | 1.10x | CN¥-157.85 Million |
| 2014 | 3.60% | 15.20% | 0.21x | 1.12x | CN¥-110.29 Million |
| 2015 | 3.88% | 16.67% | 0.20x | 1.19x | CN¥-107.90 Million |
| 2016 | 2.56% | 9.79% | 0.22x | 1.22x | CN¥-133.91 Million |
| 2017 | 2.71% | 10.44% | 0.22x | 1.21x | CN¥-134.88 Million |
| 2018 | 0.87% | 1.51% | 0.40x | 1.41x | CN¥-141.05 Million |
| 2019 | -1.77% | -2.62% | 0.46x | 1.46x | CN¥-176.31 Million |
| 2020 | 0.62% | 1.01% | 0.35x | 1.74x | CN¥-140.91 Million |
| 2021 | 0.73% | 1.31% | 0.34x | 1.63x | CN¥-139.41 Million |
| 2022 | -14.25% | -35.01% | 0.23x | 1.74x | CN¥-319.20 Million |
| 2023 | 0.86% | 1.56% | 0.34x | 1.61x | CN¥-122.95 Million |
| 2024 | -18.97% | -45.73% | 0.24x | 1.73x | CN¥-330.20 Million |
Industry Comparison
This section compares Hainan Honz Pharmaceutical Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hainan Honz Pharmaceutical Co (300086) | CN¥1.07 Billion | 29.51% | 0.75x | $371.09 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |